Enterprise Value
23.69M
Cash
285.6M
Avg Qtr Burn
-13.01M
Short % of Float
15.29%
Insider Ownership
1.71%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TERN-501 (THR-B Agonist) +/- TERN-101 (FXR agonist) Details Non-alcoholic steatohepatitis | Phase 2a Update | |
TERN-201 (VAP-1 inhibitor) Details Non-alcoholic steatohepatitis | Phase 1b Update | |
Phase 1 Data readout | ||
TERN-701 (Allosteric BCR-ABL inhib) Details Chronic myelomonocytic leukemia | Phase 1 Initiation | |
TERN-101 (FXR agonist) Details Non-alcoholic steatohepatitis | Failed Discontinued |